Description

LL37 represents the mature form of human cathelicidin, a 37-amino acid antimicrobial peptide derived from the C-terminal region of the cathelicidin precursor protein hCAP18. The compound demonstrates broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and other pathogens, making it a key component of the innate immune system. LL37 functions through multiple mechanisms including direct antimicrobial activity via membrane disruption, immunomodulatory effects on immune cells, and enhancement of host defense responses. The peptide demonstrates additional biological activities beyond antimicrobial effects, including wound healing promotion, angiogenesis modulation, and regulation of inflammatory responses. LL37 has been extensively studied for its role in various infectious and inflammatory conditions, as well as its potential as a therapeutic target or template for antimicrobial drug development. Research applications include investigation of innate immunity mechanisms, antimicrobial peptide biology, host-pathogen interactions, and the development of novel antimicrobial strategies. For research use only.